Raymond James & Associates’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $632M | Sell |
2,865,142
-164,003
| -5% | -$33.9M | 0.39% | 44 |
|
|
2024
Q2 | $596M | Buy |
3,029,145
+94,302
| +3% | +$19.5M | 0.39% | 46 |
|
|
2024
Q1 | $632M | Buy |
2,934,843
+139,125
| +5% | +$29.2M | 0.43% | 46 |
|
|
2023
Q4 | $589M | Buy |
2,795,718
+137,425
| +5% | +$29.3M | 0.44% | 41 |
|
|
2023
Q3 | $532M | Buy |
2,658,293
+82,566
| +3% | +$16.4M | 0.45% | 41 |
|
|
2023
Q2 | $477M | Buy |
2,575,727
+78,740
| +3% | +$14.6M | 0.39% | 45 |
|
|
2023
Q1 | $478M | Sell |
2,496,987
-15,062
| -0.6% | -$2.72M | 0.42% | 44 |
|
|
2022
Q4 | $422M | Buy |
2,512,049
+3,326
| +0.1% | +$578K | 0.39% | 46 |
|
|
2022
Q3 | $444M | Buy |
2,508,723
+51,405
| +2% | +$10.2M | 0.45% | 37 |
|
|
2022
Q2 | $503M | Buy |
2,457,318
+82,199
| +3% | +$17.4M | 0.49% | 33 |
|
|
2022
Q1 | $565M | Buy |
2,375,119
+76,568
| +3% | +$18M | 0.48% | 34 |
|
|
2021
Q4 | $525M | Buy |
2,298,551
+73,567
| +3% | +$16.2M | 0.42% | 39 |
|
|
2021
Q3 | $430M | Buy |
2,224,984
+83,941
| +4% | +$17M | 0.39% | 41 |
|
|
2021
Q2 | $455M | Buy |
2,141,043
+145,509
| +7% | +$30.7M | 0.41% | 39 |
|
|
2021
Q1 | $408M | Buy |
1,995,534
+260,599
| +15% | +$51.3M | 0.41% | 40 |
|
|
2020
Q4 | $316M | Sell |
1,734,935
-55,066
| -3% | -$9.36M | 0.35% | 55 |
|
|
2020
Q3 | $299M | Sell |
1,790,001
-21,259
| -1% | -$3.58M | 0.37% | 51 |
|
|
2020
Q2 | $294M | Buy |
1,811,260
+146,727
| +9% | +$26.3M | 0.39% | 50 |
|
|
2020
Q1 | $288M | Buy |
1,664,533
+89,526
| +6% | +$17.8M | 0.46% | 39 |
|
|
2019
Q4 | $316M | Buy |
1,575,007
+86,069
| +6% | +$17.7M | 0.4% | 43 |
|
|
2019
Q3 | $315M | Buy |
1,488,938
+52,659
| +4% | +$11M | 0.44% | 36 |
|
|
2019
Q2 | $279M | Buy |
1,436,279
+83,175
| +6% | +$15.3M | 0.4% | 39 |
|
|
2019
Q1 | $223M | Buy |
1,353,104
+201,486
| +17% | +$35.6M | 0.34% | 47 |
|
|
2018
Q4 | $217M | Buy |
1,151,618
+8,961
| +0.8% | +$1.65M | 0.38% | 41 |
|
|
2018
Q3 | $194M | Buy |
1,142,657
+52,203
| +5% | +$8.79M | 0.3% | 55 |
|
|
2018
Q2 | $179M | Buy |
1,090,454
+6,180
| +0.6% | +$1.01M | 0.3% | 58 |
|
|
2018
Q1 | $175M | Buy |
1,084,274
+51,331
| +5% | +$8.17M | 0.31% | 53 |
|
|
2017
Q4 | $151M | Buy |
1,032,943
+34,000
| +3% | +$4.84M | 0.28% | 69 |
|
|
2017
Q3 | $136M | Buy |
998,943
+85,387
| +9% | +$10.8M | 0.27% | 70 |
|
|
2017
Q2 | $114M | Buy |
913,556
+100,968
| +12% | +$12.1M | 0.25% | 80 |
|
|
2017
Q1 | $96.5M | Buy |
812,588
+17,632
| +2% | +$2.12M | 0.22% | 91 |
|
|
2016
Q4 | $91.7M | Sell |
794,956
-125,074
| -14% | -$13.9M | 0.23% | 87 |
|
|
2016
Q3 | $96.2M | Sell |
920,030
-17,173
| -2% | -$1.79M | 0.26% | 72 |
|
|
2016
Q2 | $91.3M | Buy |
937,203
+116,500
| +14% | +$11M | 0.29% | 68 |
|
|
2016
Q1 | $78.8M | Buy |
820,703
+25,734
| +3% | +$2.34M | 0.27% | 73 |
|
|
2015
Q4 | $72M | Buy |
794,969
+105,425
| +15% | +$9.92M | 0.26% | 75 |
|
|
2015
Q3 | $63.9M | Buy |
689,544
+40,211
| +6% | +$3.82M | 0.26% | 76 |
|
|
2015
Q2 | $60.4M | Buy |
649,333
+85,241
| +15% | +$7.95M | 0.23% | 86 |
|
|
2015
Q1 | $53.4M | Sell |
564,092
-107,607
| -16% | -$9.97M | 0.23% | 88 |
|
|
2014
Q4 | $59.5M | Buy |
671,699
+63,106
| +10% | +$5.35M | 0.29% | 65 |
|
|
2014
Q3 | $48.7M | Buy |
608,593
+50,206
| +9% | +$3.78M | 0.28% | 61 |
|
|
2014
Q2 | $39.6M | Sell |
558,387
-16,608
| -3% | -$1.17M | 0.24% | 68 |
|
|
2014
Q1 | $42.6M | Buy |
574,995
+78,652
| +16% | +$5.93M | 0.29% | 57 |
|
|
2013
Q4 | $38.9M | Buy |
496,343
+123,082
| +33% | +$9.64M | 0.29% | 58 |
|
|
2013
Q3 | $27.6M | Sell |
373,261
-26,134
| -7% | -$1.93M | 0.24% | 72 |
|
|
2013
Q2 | $30.3M | Buy |
+399,395
| New | +$26.2M | 0.29% | 62 |
|
Other funds holding CME
Raymond James & Associates's CME Position: Q3 2024 in Review
Raymond James & Associates reduced its CME Group (CME) stake by 5.4% in Q3 2024, selling an estimated $33.9M and leaving 2,865,142 shares worth $632M. The position accounts for 0.39% of the portfolio, ranked #44.
Raymond James & Associates first reported a position in CME in Q2 2013 and has held it in 46 quarters since. 1,390 funds tracked by Wall St. Rank hold CME as of Q3 2024.
- Raymond James & Associates held 2,865,142 shares of CME Group worth $632M as of Q3 2024.
- Raymond James & Associates sold 164,003 CME Group shares in Q3 2024, an estimated $33.9M.
- CME Group made up 0.39% of Raymond James & Associates's portfolio in Q3 2024, its #44 holding.
- Raymond James & Associates first reported a position in CME Group in Q2 2013 and has held it in 46 quarters since.
- 1,390 funds tracked by Wall St. Rank held CME Group as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.